

Kei Fukami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5068767/publications.pdf>

Version: 2024-02-01

59
papers

2,424
citations

218677

26
h-index

197818

49
g-index

61
all docs

61
docs citations

61
times ranked

3280
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification and Visualization of Reliable Hemodynamics Evaluation Based on Non-Contact Arteriovenous Fistula Measurement. <i>Sensors</i> , 2022, 22, 2745.	3.8	1
2	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
3	<sc>L</sc>-carnitine supplementation vs cycle ergometer exercise for physical activity and muscle status in hemodialysis patients: A randomized clinical trial. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 304-313.	0.9	10
4	Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 251-260.	1.6	2
5	Triple combination therapy with telmisartan, amlodipine, and hydrochlorothiazide ameliorates albuminuria in a normotensive rat remnant kidney model. <i>Renal Replacement Therapy</i> , 2021, 7, .	0.7	0
6	Effects of Reducing L-Carnitine Supplementation on Carnitine Kinetics and Cardiac Function in Hemodialysis Patients: A Multicenter, Single-Blind, Placebo-Controlled, Randomized Clinical Trial. <i>Nutrients</i> , 2021, 13, 1900.	4.1	7
7	Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease. <i>Toxins</i> , 2021, 13, 361.	3.4	16
8	Inhibitory effects of RAGE-aptamer on development of monocrotaline-induced pulmonary arterial hypertension in rats. <i>Journal of Cardiology</i> , 2021, 78, 12-16.	1.9	5
9	Screening of Fabry disease in patients with chronic kidney disease in Japan. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 115-125.	0.7	11
10	P1134HIGH PREVALENCE OF SLEEP-DISORDERED BREATHING AND ITS ASSOCIATION WITH RENAL FUNCTION AMONG CHRONIC KIDNEY DISEASE PATIENTS (CKD1-5,HD AND PD) : A CROSS-SECTIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
11	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). <i>Clinical and Experimental Nephrology</i> , 2020, 24, 893-909.	1.6	6
12	Carnitine deficiency is associated with decreased exercise activity in hemodialysis patients. <i>Renal Replacement Therapy</i> , 2019, 5, .	0.7	4
13	Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia. <i>CEN Case Reports</i> , 2019, 8, 205-211.	0.9	0
14	Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review. <i>BMC Nephrology</i> , 2019, 20, 469.	1.8	11
15	Uremic Toxinâ€œTargeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome. <i>Circulation Journal</i> , 2019, 84, 2-8.	1.6	17
16	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1266-1280.	1.6	21
17	RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice. <i>Scientific Reports</i> , 2018, 8, 2686.	3.3	24
18	Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 35-44.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0203046.	2.5	23
20	An Overview on Diabetic Nephropathy. , 2018, , 125-137.		0
21	Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4. Microvascular Research, 2018, 120, 90-93.	2.5	18
22	The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. Internal Medicine, 2017, 56, 841-846.	0.7	6
23	L-carnitine Supplementation Improves Self-rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis. Letters in Drug Design and Discovery, 2017, 14, 737-742.	0.7	14
24	Maternal exposure to high-fat and high-fructose diet evokes hypoadiponectinemia and kidney injury in rat offspring. Clinical and Experimental Nephrology, 2016, 20, 853-861.	1.6	24
25	Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients. BioResearch Open Access, 2016, 5, 155-158.	2.6	8
26	Receptor for advanced glycation endproducts and progressive kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 54-60.	2.0	38
27	Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology, 2015, 14, 2.	6.8	95
28	Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. International Journal of Cardiology, 2015, 185, 263-268.	1.7	85
29	Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients. Journal of Cardiovascular Pharmacology, 2015, 65, 289-295.	1.9	65
30	Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk. Rejuvenation Research, 2015, 18, 48-56.	1.8	60
31	Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney International, 2014, 85, 570-578.	5.2	39
32	Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovascular Diabetology, 2014, 13, 60.	6.8	50
33	Carnitine deficiency is associated with late-onset hypogonadism and depression in uremic men with hemodialysis. Aging Male, 2014, 17, 238-242.	1.9	11
34	Dialysate Vascular Endothelial Growth Factor Is an Independent Determinant of Serum Albumin Levels and Predicts Future Withdrawal From Peritoneal Dialysis in Uremic Patients. Therapeutic Apheresis and Dialysis, 2014, 18, 391-397.	0.9	9
35	Effects of switching from oral administration to intravenous injection of L-carnitine on lipid metabolism in hemodialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 470-474.	2.9	11
36	Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetology and Metabolic Syndrome, 2014, 6, 86.	2.7	29

#	ARTICLE	IF	CITATIONS
37	Role of AGEs-RAGE System in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 2395-2402.	1.9	143
38	DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy. <i>Diabetes</i> , 2013, 62, 3241-3250.	0.6	72
39	Potential Inhibitory Effects of L-Carnitine Supplementation on Tissue Advanced Glycation End Products in Patients with Hemodialysis. <i>Rejuvenation Research</i> , 2013, 16, 460-466.	1.8	27
40	Evidence for a Positive Association Between Serum Carnitine and Free Testosterone Levels in Uremic Men with Hemodialysis. <i>Rejuvenation Research</i> , 2013, 16, 200-205.	1.8	3
41	Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 55-62.	0.7	55
42	Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product-Induced Protein Arginine Methyltransferase-1 Expression. <i>American Journal of Pathology</i> , 2013, 182, 132-141.	3.8	125
43	PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. <i>Microvascular Research</i> , 2013, 85, 54-58.	2.5	48
44	Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 436-441.	2.0	55
45	Effects of Switching From Calcium Carbonate to Lanthanum Carbonate on Bone Mineral Metabolism in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 35-40.	0.9	13
46	An Overview of Diabetic Nephropathy. , 2012, , 145-157.		2
47	Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. <i>Nephrology</i> , 2012, 17, 689-694.	1.6	20
48	Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. <i>Pharmacological Research</i> , 2011, 63, 241-248.	7.1	50
49	Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. <i>Nephrology</i> , 2011, 16, 299-303.	1.6	21
50	Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. <i>Pharmacological Research</i> , 2010, 61, 34-39.	7.1	62
51	Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 326-330.	2.1	33
52	Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1397-1406.	0.7	33
53	Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1624-1628.	3.4	48
54	Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. <i>Microvascular Research</i> , 2008, 75, 130-134.	2.5	56

#	ARTICLE	IF	CITATIONS
55	Role of AGEs in Diabetic Nephropathy. <i>Current Pharmaceutical Design</i> , 2008, 14, 946-952.	1.9	127
56	Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 983-996.	4.1	121
57	Inhibition of NADPH Oxidase Prevents Advanced Glycation End Productâ€‘Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-â€‘Dependent Pathway. <i>Diabetes</i> , 2008, 57, 460-469.	0.6	317
58	Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention. <i>Current Drug Targets</i> , 2007, 8, 952-959.	2.1	137
59	Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1525-1533.	6.1	106